Shares of Sarepta Therapeutics (SRPT -6.3%) are notably lower on the session.
The drisapersen data "underscores [the] point that no correlation can be drawn currently between dystrophin and clinical benefit," Cowen says.
Adam Feuerstein's take: "SRPT bears sticking to script. We knew they'd link poor drisapersen dystrophin data to eteplirsen."
Note: Cowen is still "bullish on SRPT shares."